Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP)

Blood Cells, Molecules, and Diseases

Volumn 55, Issue 1, 2015, Pages 40-47

  Barone, Angelica ^a   Lucarelli, Annunziata ^b   Onofrillo, Daniela ^c   Verzegnassi, Federico ^d   Bonanomi, Sonia ^e   Cesaro, Simone ^f   Fioredda, Francesca ^g   Iori, Anna Paola ^h   Ladogana, Saverio ⁱ   Locasciulli, Anna ^j   Longoni, Daniela ^e   Lanciotti, Marina ^g   Macaluso, Alessandra ^k   Mandaglio, Rosalba ^l   Marra, Nicoletta ^m   Martire, Baldo ⁿ   Maruzzi, Matteo ⁱ   Menna, Giuseppe ^m   Notarangelo, Lucia Dora ^o   Palazzi, Giovanni ^p   Pillon, Marta ^q   Ramenghi, Ugo ^r   Russo, Giovanna ^s   Svahn, Johanna ^g   Timeus, Fabio ^t   Tucci, Fabio ^u   Cugno, Chiara ^v   Zecca, Marco ^v   Farruggia, Piero ^k   Dufour, Carlo ^g   Saracco, Paola ^r   more..

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b VITO FAZZI HOSPITAL   (Italy)

^c Pescara Public Hospital   (Italy)

^d INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^e SAN GERARDO HOSPITAL   (Italy)

^f Divisione Chirurgia Generale C Borgo Roma Hospital   (Italy)

^g G GASLINI INSTITUTE   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^j SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^k Gastroenterology Unit   (Italy)

^l PUGLIESE CIACCIO HOSPITAL   (Italy)

^m SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

ⁿ UNIVERSITY OF BARI   (Italy)

^o SPEDALI CIVILI   (Italy)

^p UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^q UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^r UNIVERSITY OF TURIN   (Italy)

^s UNIVERSITY OF CATANIA   (Italy)

^t REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^u UNIVERSITY OF FLORENCE   (Italy)

^v FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

more..

Author keywords

Acquired aplastic anemia; Childhood; Guidelines

Indexed keywords

ALEMTUZUMAB; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DANAZOL; DEFERASIROX; ELTROMBOPAG; FLUDARABINE; METHOTREXATE; OXYMETHOLONE; PENTAMIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; ORGANOPHOSPHATE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; APLASTIC ANEMIA; ARTICLE; BLOOD EXAMINATION; BONE MARROW BIOPSY; CHELATION THERAPY; CHILDHOOD; CHROMOSOME ANALYSIS; CONTROLLED CLINICAL TRIAL (TOPIC); DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DONOR; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; FAMILY HISTORY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LOW DRUG DOSE; MATCHED SIBLING DONOR; META ANALYSIS (TOPIC); NON SEVERE APLASTIC ANEMIA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL EXAMINATION; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERE APLASTIC ANEMIA; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPHERESIS; UNRELATED DONORS; VACCINATION; VERY SEVERE APLASTIC ANEMIA; ANEMIA, APLASTIC; BONE MARROW; CHEMICALLY INDUCED; CHILD; DISEASE MANAGEMENT; DRUG EFFECTS; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; PANCYTOPENIA; PATHOLOGY; PROCEDURES; SIBLING;

ANEMIA, APLASTIC; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTILYMPHOCYTE SERUM; ANTIRHEUMATIC AGENTS; BONE MARROW; CHILD; CYCLOSPORINE; DISEASE MANAGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGANOPHOSPHATES; PANCYTOPENIA; SIBLINGS; UNRELATED DONORS;

EID: 84929223977     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2015.03.007     Document Type: Article

References (54)

1. Fioredda F., Calvillo M., Bonanomi S., Coliva T., Tucci F., Farruggia P., et al. Congenital and acquired neutropenias consensus guidelines on therapy and follow-up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica). Am. J. Hematol. Feb 2012, 87(2):238-243.
2. Marsh J.C., Ball S.E., Cavenagh J., Darbyshire P., Dokal I., Gordon-Smith E.C., et al. British Committee for Standards in Haematology. Guidelines for the diagnosis and management of aplastic anaemia. Br. J. Haematol. 2009, 147:43-70.
3. Montané E., Ibáñez L., Vidal X., Ballarín E., Puig R., García N., et al. Catalan Group for Study of Agranulocytosis and Aplastic Anemia. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica 2008, 93:518-523.
4. Young N.S., Kaufman D.W. The epidemiology of acquired aplastic anemia. Haematologica 2008, 93:489-492.
5. Young N.S., Calado R.T., Scheinberg P. Current concepts in the patho-physiology and treatment of aplastic anemia. Blood 2006, 108:2509-2519.
6. Dufour C., Ferretti E., Bagnasco F., Burlando O., Lanciotti M., Ramenghi U., et al. Marrow Failure Study Group of the AIEOP. Changes in cytokine profile pre- and post-immunosuppression in acquired aplastic anemia. Haematologica 2009, 94:1743-1747.
7. Dufour C., Svahn J., Bacigalupo A., Longoni D., Varotto S., Iori A.P., et al. Genetic polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 and the risk of acquired idiopathic aplastic anemia in Caucasian patients. Haematologica January 2005, 90:1027-1031.
8. Camitta B.M., Thomas E.D., Nathan D.G., Santos G., Gordon-Smith E.C., Gale R.P., et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood 1976, 1:63-70.
9. Bacigalupo A., Hows J., Gluckman E., Nissen C., Marsh J., Van Lint M.T., et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br. J. Haematol. 1988, 2:177-182.
10. Rovo A., Tichelli A., Dufour C. Diagnosis of aplastic anemia. Bone Marrow Transplant. 2013, 48:162-167.
11. Shimamura A. Clinical approach to marrow failure. Hematology Am. Soc. Hematol. Educ. Program 2009, 329-337.
12. Niemeyer C.M., Baumann I. Classification of childhood AA and MDS. Hematology Am. Soc. Hematol. Educ. Program 2011, 2011:84-89.
13. Dufour C., Pillon M., Passweg J., Socié G., Bacigalupo A., Franceschetto G., et al. Outcome of aplastic anemia in adolescence. A survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2014, 99(10):1574-1581.
14. Howard S.C., Naidu P.E., Hu X.J., Jeng M.R., Rodriguez-Galindo C., Rieman M.D., et al. Natural history of moderate aplastic anemia in children. Pediatr. Blood Cancer 2004, 43:545-551.
15. Passweg J.R., Socié G., Hinterberger W., Bacigalupo A., Biggs J.C., Camitta B.M., et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved?. Blood 1997, 90:858-864.
16. Korthof E.T., Békássy A.N., Hussein A.A. Management of acquired aplastic anemia in children. Bone Marrow Transplant. 2013, 4:191-195.
17. Kobayashi R., Yabe H., Hara J., Morimoto A., Tsuchida M., Mugishima H., Japan Childhood Aplastic Anemia Study Group, et al. Preceding immunosuppressive therapy with antithymocyte globulin and cyclosporin increases the incidence of graft rejection in children with aplastic anaemia who underwent allogeneic bone marrow transplantation from HLA-identical siblings. Br. J. Haematol. 2006, 135:693-696.
18. Schrezenmeier H., Passweg J.R., Marsh J.C., Bacigalupo A., Bredeson C.N., Bullorsky E., et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007, 110:1397-1400.
19. Scheinberg P., Wu C.O., Nunez O., Young N.S. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J. Pediatr. 2008, 153:814-819.
20. Führer M., Rampf U., Baumann I., Faldum A., Niemeyer C., Janka-Schaub G., et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood 2005, 106:2102-2104.
21. Scheinberg P., Nunez O., Weinstein B., Scheinberg P., Biancotto A., Wu C.O., et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N. Engl. J. Med. 2011, 365:430-438.
22. Marsh J.C., Bacigalupo A., Schrezenmeier H., Tichelli A., Risitano A.M., Passweg J.R., et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood Jun 7 2012, 119(23):5391-5396.
23. Saracco P., Quarello P., Iori A.P., Zecca M., Longoni D., Svahn J., et al. Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up. Br. J. Haematol. Jan 2008, 140(2):197-205.
24. Bacigalupo A., Bruno B., Saracco P., Di Bona E., Locasciulli A., Locatelli F., et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midollo Osseo (GITMO). Blood 2000, 95:1931-1934.
25. Marsh J.C., Gupta V., Lim Z., Ho A.Y., Ireland R.M., Hayden J., et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft versus host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood 2011, 118:2351-2357.
26. Samarasinghe S., Steward C., Hiwarkar P., Saif M.A., Hough R., Webb D., et al. Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience. Br. J. Haematol. 2012, 157(3):339-346.
27. Bhatnagar N., Wynn R., Velangi M., Vora A., Bonney D., Gibson B., et al. Upfront matched and mismatched unrelated donor transplantation in paediatric idiopathic severe aplastic anaemia: a United Kingdom multicentre retrospective experience. Bone Marrow Transplant. 2014, 49(S1).
28. Samarasinghe S., Marsh J., Dufour C. Immune suppression for childhood acquired aplastic anaemia and myelodysplastic syndrome: where next?. Haematologica 2014, 99(4):597-599.
29. Kamio T., Ito E., Ohara A., Japan Childhood Aplastic Anemia Study Group, et al. Relapse of aplastic anemia in children after immunosuppressive therapy: a report from the Japan Childhood Aplastic Anemia Study Group. Haematologica 2011, 96:814-819.
30. Maciejewski J.P., Risitano A.M. Aplastic anemia: management of adult patients. Hematology Am. Soc. Hematol. Educ. Program 2005, 110-117.
31. Rosenfeld S., Follmann D., Nunez O., Young N.S. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003, 289:1130-1135.
32. Scheinberg P., Wu C.O., Nunez O., et al. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br. J. Haematol. 2009, 144:206-216.
33. Scheinberg P., Nunez O., Young N.S. Retreatment with rabbit anti-thymocyte globulin and cyclosporin for patients with relapsed or refractory severe aplastic anaemia. Br. J. Haematol. 2006, 133:622-627.
34. Kosaka Y., Yagasaki H., Sano K., et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood 2008, 111:1054-1059.
35. Gupta V., Gordon-Smith E.C., Cook G., et al. A third course of anti-thymocyte globulin in aplastic anaemia is only beneficial in previous responders. Br. J. Haematol. 2005, 129:110-117.
36. Scheinberg P., Nunez O., Weinstein B., et al. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood 2012, 119:345-354.
37. Olnes M.J., Scheinberg P., Calvo K.R., et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N. Engl. J. Med. 2012, 367:11-19.
38. Desmond R., Townsley D.M., Dumitriu B., et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood 2014, 123(12):1818-1825.
39. Leleu X., Terriou L., Duhamel A., et al. Long-term outcome in acquired aplastic anemia treated with an intensified dose schedule of horse antilymphocyte globulin in combination with androgens. Ann. Hematol. 2006, 85:711-716.
40. Chuhjo T., Yamazaki H., Omine M., Nakao S. Danazol therapy for aplastic anemia refractory to immunosuppressive therapy. Am. J. Hematol. 2008, 83:387-389.
41. Jaime-Pérez J.C., Colunga-Pedraza P.R., Gómez-Ramírez C.D., et al. Danazol as first-line therapy for aplastic anemia. Ann. Hematol. 2011, 90:523-527.
42. Brodsky R.A., Chen A.R., Dorr D., et al. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood 2010, 115:2136-2141.
43. Scheinberg P., Townsley D., Dumitriu B., et al. "Moderate" dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution. Blood 2014, 124(18):2820-2823.
44. Sloand E.M., Olnes M.J., Weinstein B., et al. Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab. Haematologica 2010, 95:382-387.
45. Scheinberg P., Fischer S.H., Li L., et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 2007, 109:3219-3224.
46. Vamvakas E.C. Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions. Transfus. Med. Rev. 1998, 12:258-270.
47. Serious Hazards of Transfusion (SHOT) Annual Report Website:. http://www.shotuk.org.
48. Vamvakas E.C. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus. Med. Rev. 2005, 19:181-199.
49. Marsh J., Socie G., Tichelli A., European Group for Blood and Marrow Transplantation (EBMT) Severe Aplastic Anaemia Working Party, et al. Should irradiated blood products be given routinely to all patients with aplastic anaemia undergoing immunosuppressive therapy with antithymocyte globulin (ATG)? A survey from the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Br. J. Haematol. 2010, 150:377-379.
50. Treleaven J., Gennery A., Marsh J., et al. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. Br. J. Haematol. 2011, 152:35-51.
51. Lehrnbecher T., Phillips R., Alexander S., International Pediatric Fever and Neutropenia Guideline Panel, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J. Clin. Oncol. 2012, 30:4427-4438.
52. Valdez J.M., Scheinberg P., Young N.S., Walsh T.J. Infections in patients with aplastic anemia. Semin. Hematol. 2009, 46:269-276.
53. Hendry C.L., Sivakumaran M., Marsh J.C., Gordon-Smith E.C. Relapse of severe aplastic anaemia after influenza immunization. Br. J. Haematol. 2002, 119:283-284.
54. Lee J.W., Yoon S.S., Shen Z.X., EPIC study investigators, et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood 2010, 116:2448-2454.